Sunita D. Nasta, MD, FACP
Professor of Clinical Medicine (Hematology-Oncology)
Attending Physician, Hospital of the University of Pennsylvania
Chair, Institutional Review Board #3
Chair, Clinical Trials Scientific Research Monitoring Committee
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-159
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-159
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-3933
Fax: 215-615-5887
Fax: 215-615-5887
Education:
BS (Microbiology & Immunology)
Stanford University, Palo Alto, CA , 1991.
MD
Medical College of Virginia, Richmond, VA, 1995.
Permanent linkBS (Microbiology & Immunology)
Stanford University, Palo Alto, CA , 1991.
MD
Medical College of Virginia, Richmond, VA, 1995.
Description of Research Expertise
Clinical trials in non-Hodgkin's lymphoma, phase I, II and IIIClinical trials in Castleman Diseaes
Description of Clinical Expertise
1.Management of patients with Non-Hodgkin's lymphoma, Hodgkin's Lymphoma, multiple myeloma, acute and chronic leukemias with standard therapy as well as clinical experimental therapies using new agents.2. Bone Marrow and Stem Cell Transplantation, autologous and allogeneic.
3. Special interest in treating patients with aggressive non-Hodgkin's lymphoma, lymphoma in the elderly and lymphoma in the pregnant patient.
4. Special interest in the long-term follow-up of patients with Hodgkin's lymphoma and survivors issues.
5. Management of patients with histiocytic disorders
6. Management of patients with Castleman disease.
Selected Publications
Landsburg DJ, Nasta SD, Svoboda J, Gerson JN, Schuster SJ, Barta SK, Chong EA, Difilippo H, Weber E, Cunningham K, Catania C, Garfall AL, Stadtmauer EA, Frey NV, Porter DL: Survival outcomes for patients with relapsed/refractory aggressive B cell lymphomas following receipt of high dose chemotherapy/autologous stem transplantation and/or chimeric antigen receptor-modified T cells. Transplantation and Cellular Therapy May 19 2023.Ahmed N, Wesson W, Mushtaq MU, Porter DL, Nasta SD, Brower J, Bachanova V, Hu M, Nastoupil LJ, Oluwole OO, Patel VG, Oliai C, Riedell PA, Bishop MR, Shah GL, Perales MA, Schachter L, Maziarz RT, McGuirk JP: Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma. Transplantation and Cellular Therapy Apr 27 2023.
Yegya-Raman N, Wright CM, LaRiviere MJ, Baron JA, Lee DY, Landsburg DJ, Svoboda J, Nasta SD, Gerson JN, Barta SK, Chong EA, Schuster SJ, Maity A, Facciabene A, Paydar I, Plastaras JP: Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy. Clinical and Translational Radiation Oncology 39: 100587, Mar 2023.
Ghilardi G, Chong EA, Svoboda J, Wohlfarth P, Nasta SD, Williamson S, Landsburg JD, Gerson JN, Barta SK, Pajarillo R, Myers J, Chen AI, Schachter L, Yelton R, Ballard HJ, Hodges Dwinal A, Gier S, Victoriano D, Weber E, Napier E, Garfall A, Porter DL, Jäger U, Maziarz RT, Ruella M, Schuster SJ: Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Ann Oncol 33(9): 916-928, Sep 2022 Notes: doi: 10.1016/j.annonc.2022.05.521. Epub 2022 Jun 9. PMID:
Elise A Chong 1, Cécile Alanio 2 3 4, Jakub Svoboda 1, Sunita D Nasta 1, Daniel J Landsburg 1, Simon F Lacey 5 6, Marco Ruella 1 5, Siddharth Bhattacharyya 6, E John Wherry 2 3 4, Stephen J Schuster 1: Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy Blood 139(7): 1026-1038, Feb 17 2022 Notes: doi: 10.1182/blood.2021012634.
Landsburg DJ, Nasta SD, Gerson JN, Svoboda J, Chong EA, Schuster SJ, Barta SK, Robinson KW, Hughes ME.: Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy. Leuk Lymphoma 63(1): 243-246. Jan 2022 Notes: doi: 10.1080/10428194.2021.1971224. Epub 2021 Aug 26. PMID:34435548
Landsburg DJ, Morrissette JJD, Schuster SJ, Nasta SD, Gerson JN, Barta SK, Svoboda J, Chong EA, Lim MS: Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas. Oncotarget 13: 1237-1244, Nov 17 2022.
Nasta SD, Hughes ME, Namoglu EC, Garfall A, DiFilippo H, Ballard HJ, Barta SK, Chong EA, Frey NV, Gerson JN, Landsburg DJ, Ruella M, Schuster SJ, Svoboda J, Weber E, Porter DL: Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting. Clin Lymphoma Myeloma Leuk. Volume 22, Issue 8, August 2022, Pages e730-e737 (eds.). 22(8): e730-e737, August 2022 Notes: doi: 10.1016/j.clml.2022.04.012.
Nasta SD.: Making Progress in PTCL: Significant Unmet Needs. Oncology (Williston Park) 36(5): 296, May 9 2022 Notes: doi: 10.46883/2022.25920961.
Weiner DM, Lewis DJ, Spaccarelli NG, Clark RA, Nasta SD, Loren AW, Rook AH, Kim EJ.: Management of relapsed cutaneous T-Cell lymphoma following allogeneic hematopoietic stem cell transplantation: Review with representative patient case. Dermatol Ther. April 27 2022 Notes: doi: 10.1111/dth.15538. Online ahead of print. e15538.